A nationwide survey on participation in cardiac rehabilitation among patients with coronary heart disease using health claims data in Japan

Shosuke Ohtera1,2, Genta Kato3,2, Hiroaki Ueshima1, Yukiko Mori1, Yuka Nakatani4, Neiko Ozasa5, Takeo Nakayama4 & Tomohiro Kuroda1

Poor implementation and variable quality of cardiac rehabilitation (CR) for coronary heart disease (CHD) have been a global concern. This nationwide study aimed to clarify the implementation of and participation in CR among CHD patients and associated factors in Japan. We conducted a retrospective cohort study using data extracted from the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Patients who underwent percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in 2017–2018 were included. Aspects of CR were assessed in terms of (1) participation in exercise-based CR, (2) pharmacological education, and (3) nutritional education. Of 87,829 eligible patients, 32% had participated in exercise-based CR, with a mean program length of 40 ± 71 days. CABG was associated with higher CR participation compared to PCI (OR 10.2, 95% CI 9.6–10.8). Patients living in the Kyushu region were more likely to participate in CR (OR 2.59, 95% CI 2.39–2.81). Among patients who participated in CR, 92% received pharmacological education, whereas only 67% received nutritional education. In Japan, the implementation of CR for CHD is insufficient and involved varying personal, therapeutic, and geographical factors. CR implementation needs to be promoted in the future.

Coronary heart disease (CHD) is the top cause of death globally, accounting for approximately 10 million deaths in 2016. In Japan, heart disease is the second leading cause of death; 20% and 24% of deaths are attributable to ischemic heart disease and heart failure, respectively. Although the widespread use of percutaneous coronary intervention (PCI) has improved short-term outcomes in acute coronary syndrome, including acute myocardial infarction and unstable angina, subsequent development of heart failure has been problematic. Exercise-based cardiac rehabilitation (CR) for patients with CHD reduces risks of cardiac mortality and hospital admission, and there is mounting evidence that exercise-based CR and patient education are beneficial for improving health-related quality of life. Thus, clinical practice guidelines internationally recommend comprehensive CR that includes exercise intervention, control of coronary risk factors, physical activity, and patient education by multidisciplinary professionals, as well as quality measurements, for secondary prevention of cardiovascular diseases. However, previous studies demonstrated the lack of availability and delivery of CR for eligible patients, suggesting the need for interventions that promote patient utilization of CR, such as face-to-face or technology-based communication by nurses and allied health professionals.

In Japan, some studies suggested that CR is underutilized, and that ST-segment-elevation myocardial infarction and coronary artery bypass grafting (CABG) are factors that facilitate patient participation in CR.
However, no study has clarified the rate of CR participation among CHD patients in Japan at the national level. In this study, we used a national database of health claims data to analyze rates of CR implementation and participation among Japanese patients with CHD, and to explore factors associated with the use of CR based on individual and hospital information.

**Methods**

**Study design and data source.** We conducted a retrospective cohort study using data extracted from the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB), which collects claims records on insured health care services provided to citizens under universal health coverage in Japan, except the portion of public services not covered by universal health care, such as medical assistance for welfare recipients (equivalent to 7% of national health care costs). The database was created for the development, implementation, and evaluation of medical care expenditure regulation plans based on the “Act on Assurance of Medical Care for Elderly People” enacted in April 2008. Researchers and policy makers can acquire NDB data for the purpose of promoting evidence-based policy making with the aim to improve health service quality, in accordance with “the schedule of new information network technique strategy” decided by the Japanese Cabinet in June 2010. The Ministry of Health, Labour and Welfare began providing NDB data in 2011 and original studies using the data have been published in a variety of medical research areas. In this study, we accessed data from the NDB On-site Research Center at Kyoto University Hospital. For data cleaning, a patient-matching technique was used according to a previous study. This study was approved by the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine and performed in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects established by the Ministry of Health, Labour and Welfare. The Ethics Committee of Kyoto University Graduate School and Faculty of Medicine waived the requirement for informed consent, since this study used anonymized data provided in accordance with legal provisions.

**Study setting and population.** Patients aged ≥ 40 years who underwent PCI or CABG for the first time in the past three years between April 2017 and March 2018 in Japan were included in this study. We determined the onset of CHD in these patients, and followed them for up to one year after PCI/CABG to observe aspects of CR services. The sample size was equivalent to the source population with the above inclusion criteria. We identified health claims indicating the provision of PCI or CABG using billing codes for surgical procedures assigned to the past three years between April 2017 and March 2018 in Japan were included in this study. We determined the number of patients who underwent combined coronary bypass grafting and heart valve surgery (replacement or repair). We identified PCI by treatment codes “K546 (percutaneous coronary angioplasty)”, “K547 (percutaneous coronary athereectomy)”, “K548 (percutaneous coronary angioplasty (with special catheter))”, “K549 (percutaneous coronary stenting)”, “K550 (intracoronary thrombolysis)”, “K550-2 (percutaneous coronary artery thrombectomy)” or “K551 (coronary angioplasty (thromboendarterectomy))”, and CABG by “K552 (coronary artery and aortic bypass grafting)” or “K552-2 (coronary artery and aortic bypass grafting (not using artificial heart–lung)).”

**Measurements.** We assessed patient participation in the three aspects of CR by referring to a previous study that proposed a set of quality indicators for CR in Japan. The first aspect is exercise-based CR within a year after hospitalization for PCI or CABG. We also assessed the duration of participation in CR regardless of whether it was carried out in an inpatient or outpatient setting. In Japan, inpatient CR is prescribed by physicians in acute care hospitals. After discharge, CR services can be continued on an outpatient basis. Home-based CR is currently not reimbursed by national health insurance. Whether patients participate in inpatient CR or outpatient CR, there is no standardized frequency or duration for programs. For the purposes of this study, participation in CR was defined as having attended a program one or more times. Duration of CR (number of dates) was handled as a continuous variable. In addition, the percentage of hospitals that provided CR among those that performed PCI or CABG was calculated by region. The second aspect is pharmacological education, which was determined by reimbursement records from when a pharmacist provided medication instruction or support to inpatients with physician consent, or when a health care professional provided guidance on medication to patients after discharge. The third aspect is nutritional education, which was determined by reimbursement records from when a dietician provided dietary guidance to inpatients or outpatients under physician instruction. We used medical practice billing codes to identify these aspects, e.g., “180,077,410 (Cardiovascular Disease Rehabilitation Fee (1))” and “180,027,510 (Cardiovascular Disease Rehabilitation Fee (2))” for exercise-based CR.

As covariates, we selected sex, age, type of procedure (PCI or CABG), comorbidities in the past three years before the procedure (diabetes, hypertension, and dyslipidemia, which are coronary risk factors), and the Charlson comorbidity index (CCI). Participants were divided into 5-year age groups due to the nature of the database. In addition, regarding hospitals where eligible patients underwent PCI or CABG, hospital volume (i.e., the number of patients who undergo PCI or CABG per year) and hospital location (divided into eight regions in Japan) were examined.

**Statistical analysis.** Univariate analysis of variables was performed for the three aspects of CR (participation in exercise-based CR, pharmacological education, and nutritional education). Multivariable logistic regression was used to estimate factors associated with the three aspects of CR. R version 3.4.1 was used for all analyses, with p < 0.05 considered significant.
### Results

**Participation in Exercise-based CR.** A total of 87,829 patients from 1411 hospitals were eligible for this study, comprising 80,794 (92%) PCI patients and 7035 (8%) CABG patients (Table 1). Mean age was 66.6 ± 10.2 years. In total, 28,159 (32%) patients participated in exercise-based CR within a year after hospital admission due to CHD. Mean program length was 39.9 ± 71.4 days. Among patients who underwent PCI and CABG, 22,554 (28%) and 5605 (80%) participated in CR programs, respectively (Table 2). The rate of participation varied among eight regions where the hospitals were located, ranging from 27.8% (Shikoku) to 45.1% (Kyushu). In a logistic regression model, CABG was associated with higher CR participation compared to PCI (OR 10.2, 95% CI 9.6–10.8), younger age was associated with lower CR participation compared to age ≥ 75 years (OR 0.81, 95% CI 0.78–0.85 for age 65–74 years, OR 0.79, 95% CI 0.76–0.82 for age 40–64 years), and participants in Kyushu and Chugoku regions (western Japan) were more likely to participate in CR (OR 2.59, 95% CI 2.39–2.81 and OR 1.81, 95% CI 1.66–1.98, respectively). The proportion of hospitals providing CR among the target facilities was high in Chugoku and Shikoku regions (Supplementary Table S1).

| Age | Eligible patients, N (%) |
|-----|--------------------------|
| 40–64 | 31,796 (36.2) |
| 65–74 | 32,453 (37.0) |
| ≥75 | 23,580 (26.8) |

| Sex | Eligible patients, N (%) |
|-----|--------------------------|
| Male | 69,929 (79.6) |
| Female | 17,900 (20.4) |

| PCI/CABG | Eligible patients, N (%) |
|---------|--------------------------|
| PCI | 80,794 (92) |
| CABG | 7035 (8.0) |

| Coronary risk factors | Eligible patients, N (%) |
|-----------------------|--------------------------|
| Diabetes | YES | 67,753 (77.1) |
| | NO | 20,076 (22.9) |
| Hypertension | YES | 30,987 (35.3) |
| | NO | 56,842 (64.7) |
| Dyslipidemia | YES | 28,900 (32.9) |
| | NO | 58,929 (67.1) |

| Charlson comorbidity index | Eligible patients, N (%) |
|-----------------------------|--------------------------|
| ≤2 | 65,115 (74.1) |
| 3 | 11,201 (12.8) |
| ≤4 | 11,513 (13.1) |

| Hospital information | Eligible patients, N (%) |
|----------------------|--------------------------|
| Patient volume per year | 12,832 (14.6) |
| < 50 | 20,776 (23.7) |
| 100–150 | 17,084 (19.5) |
| ≥200 | 25,380 (28.9) |

| Region | Eligible patients, N (%) |
|--------|--------------------------|
| Hokkaido | 5313 (6.0) |
| Tohoku | 4232 (4.8) |
| Kanto | 32,958 (37.5) |
| Chubu | 13,563 (15.4) |
| Kinki | 17,184 (19.6) |
| Chugoku | 5011 (5.7) |
| Shikoku | 1701 (1.9) |
| Kyushu | 7867 (9.0) |

Table 1. Characteristics of eligible patients.PCI percutaneous coronary intervention, CABG coronary artery bypass grafting.
Nutritional and pharmacological education. Among CR participants, 25,935 (92.1%) were provided with pharmacological education. CABG (OR: 1.26, 95% CI 1.12–1.42), diabetes (OR 1.29, 95% CI 1.15–1.44), and dyslipidemia (OR 1.28, 95% CI 1.16–1.41) were factors associated with higher provision of pharmacological education (Table 3). Nutritional education was provided to 18,743 (66.6%) CR participants. CABG was associated with lower provision of nutritional education (OR 0.66, 95% CI 0.62–0.71) (Table 4).

Discussion
This study clarified the implementation of and participation in CR among patients who underwent PCI or CABG between April 2017 and March 2018 in Japan using nationwide claims data. Only 32% of eligible patients participated in exercise-based CR, with a mean program length of 40 days, despite that both inpatients and outpatients were included in the analysis. CABG was associated with a higher odds of CR participation compared to PCI,
and more hospitals in the western part of Japan (i.e., Kyushu and Chugoku regions) performed CR. Moreover, among CR participants, 92% were provided with pharmacological education, whereas only 67% were provided with nutritional education.

Previous studies examined the status of CR referral and suggested that factors such as acute myocardial infarction, cardiac surgery, accessibility to hospitals, hospitals with greater PCI volume, and hospitals that perform cardiovascular procedures were associated with increased referrals. In addition, waiting time from referral to enrollment and follow-up sessions were measured as aspects of participation in CR after referral in some studies. However, the nationwide status of CR participation has not been clarified in Japan.

The present study revealed a higher rate of CR participation among patients who underwent PCI or CAGB than that reported in a previous study (24%) focused on a younger Japanese population aged ≤ 65 years. We consider this to be reasonable, given that our multivariable regression model estimated younger age to be associated with a lower odds of CR participation. Nevertheless, as has been pointed out previously, this level of participation

| Table 3. Assessment of participation in pharmacological education. OR odds ratio, CI confidence interval, PCI percutaneous coronary intervention, CAGB coronary artery bypass grafting. |

| Age | Patients who participated in pharmacological education, n (%) | Patients who did not participate in pharmacological education, n (%) | Rate of participation in pharmacological education, % | Logistic regression n = 25,935 n = 2224 OR (95%CI) | P value |
|-----|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------|-------------------------------------------------|---------|
| 40–64 | 10,001 (38.6) | 845 (38.0) | 92.2 | 0.94 (0.85–1.05) | 0.26 |
| 65–74 | 9318 (35.9) | 811 (36.5) | 92.0 | 0.90 (0.80–1.02) | 0.10 |
| ≥ 75 | 6616 (25.5) | 568 (25.5) | 92.1 | Ref |
| Sex | Male | 20,744 (80.0) | 1778 (79.9) | 92.1 | Ref |
| | Female | 5191 (20.0) | 446 (20.1) | 92.1 | 1.00 (0.89–1.12) | 0.98 |
| PCI/CAGB | PCI | 20,714 (79.9) | 1840 (82.7) | 91.8 | Ref |
| | CAGB | 5221 (20.1) | 384 (17.3) | 93.1 | 1.26 (1.12–1.42) | <0.01 |
| Coronary risk factors | Diabetes | | | | |
| | Yes | 19,642 (75.7) | 1763 (79.3) | 91.8 | 1.29 (1.15–1.44) | <0.01 |
| | No | 6293 (24.3) | 461 (20.7) | 93.2 | Ref |
| Hypertension | Yes | 8048 (31.0) | 786 (35.3) | 91.1 | 1.11 (1.00–1.23) | 0.04 |
| | No | 17,887 (69.0) | 1438 (64.7) | 92.6 | Ref |
| Dyslipidemia | Yes | 8133 (31.4) | 844 (37.9) | 90.6 | 1.28 (1.16–1.41) | <0.01 |
| | No | 17,802 (68.6) | 1380 (62.1) | 92.8 | Ref |
| Charlson comorbidity index | ≤ 2 | 17,899 (69) | 1511 (67.9) | 92.2 | Ref |
| | 3 | 4184 (16.1) | 339 (15.2) | 92.5 | 0.95 (0.83–1.08) | 0.39 |
| | ≥ 4 | 3852 (14.9) | 374 (16.8) | 91.2 | 0.76 (0.67–0.86) | <0.01 |
| Hospital information | Patient volume per year | | | | |
| < 50 | 2655 (10.2) | 338 (15.2) | 88.7 | Ref |
| 50–100 | 6254 (24.1) | 445 (20.0) | 93.4 | 1.81 (1.55–2.11) | <0.01 |
| 100–150 | 5277 (20.3) | 549 (24.7) | 90.6 | 1.10 (0.95–1.28) | 0.21 |
| 150–200 | 3840 (14.8) | 272 (12.2) | 93.4 | 1.54 (1.29–1.84) | <0.01 |
| ≥ 200 | 7909 (30.5) | 620 (27.9) | 92.7 | 1.48 (1.27–1.71) | <0.01 |
| Region | Hokkaido | 1375 (5.3) | 129 (5.8) | 91.4 | Ref |
| | Tohoku | 986 (3.8) | 251 (11.3) | 79.7 | 0.35 (0.27–0.44) | <0.01 |
| | Kantō | 8707 (33.6) | 825 (37.1) | 91.3 | 1.02 (0.84–1.24) | 0.82 |
| | Chubu | 4172 (16.1) | 287 (12.9) | 93.6 | 1.44 (1.15–1.79) | <0.01 |
| | Kinki | 5210 (20.1) | 273 (12.3) | 95.0 | 1.83 (1.46–2.27) | <0.01 |
| | Chugoku | 1849 (7.1) | 76 (3.4) | 96.1 | 2.37 (1.77–3.19) | <0.01 |
| | Shikoku | 441 (1.7) | 32 (1.4) | 93.2 | 1.46 (0.98–2.22) | 0.07 |
| | Kyushu | 3195 (12.3) | 351 (15.8) | 90.1 | 0.88 (0.70–1.08) | 0.23 |
is lower compared to other countries\textsuperscript{38}. In addition, while previous studies in North America reported that men are more likely to participate in CR than women, the present study found no difference between men and women. This finding, however, is consistent with the results of previous studies in Japan\textsuperscript{25,39–41}. We also found that patients who underwent CABG were more likely to participate in CR than those who underwent PCI, consistent with a previous report\textsuperscript{25}. Some regions in the western part of Japan performed CR more than other regions, showing geographical variation in the implementation of CR as previously reported in the United States\textsuperscript{18,20}. Our results also suggested that the supply of CR programs is higher in the western part of Japan, which is in line with previous reports that the supply of medical care in Japan might be in a state of “west high, east low”\textsuperscript{42,43}. These results suggest disparities in CR implementation in different regions of the country, although further investigation will be needed to clarify this aspect based on the waiting list of CR and participation in programs in rural versus urban areas. Furthermore, despite the fact that CR is covered by public health insurance in Japan for up to five months, the mean CR program length was roughly one month in both inpatient and outpatient settings. This

### Table 4.
Assessment of participation in nutritional education.

|                          | Patients who participated in nutritional education, n (%) | Patients who did not participate in nutritional education, n (%) | Rate of participation in nutritional education, % | Logistic regression | P value |
|--------------------------|----------------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------|---------------------|--------|
|                          | n = 18,743                                                | n = 9416                                                      |                                                 |                     |        |
| Age                      |                                                          |                                                               |                                                 |                     |        |
| 40–64                    | 7868 (42.0)                                               | 2978 (31.6)                                                   | 72.5                                            | 0.85 (0.80–0.90)    | <0.01  |
| 65–74                    | 6866 (26.5)                                               | 3263 (34.7)                                                   | 67.8                                            | 0.60 (0.56–0.70)    | <0.01  |
| ≥ 75                     | 4009 (15.5)                                               | 3175 (33.7)                                                   | 55.8                                            |                     |        |
| Sex                      |                                                          |                                                               |                                                 |                     |        |
| Male                     | 15,232 (58.7)                                             | 7290 (77.4)                                                   | 67.6                                            | 0.92 (0.86–1.00)    | 0.01   |
| Female                   | 3511 (13.5)                                               | 2126 (22.6)                                                   | 62.3                                            |                     |        |
| PCI/CABG                 |                                                          |                                                               |                                                 |                     |        |
| PCI                      | 15,557 (60.0)                                             | 6997 (74.3)                                                   | 69.0                                            |                     |        |
| CABG                     | 3186 (12.3)                                               | 2419 (25.7)                                                   | 56.8                                            | 0.66 (0.62–0.70)    | <0.01  |
| Coronary risk factors    |                                                          |                                                               |                                                 |                     |        |
| Diabetes                 |                                                          |                                                               |                                                 |                     |        |
| Yes                      | 14,146 (54.5)                                             | 7259 (77.1)                                                   | 66.1                                            | 1.17 (1.10–1.20)    | <0.01  |
| No                       | 4597 (17.7)                                               | 2157 (22.9)                                                   | 68.1                                            |                     |        |
| Hypertension             |                                                          |                                                               |                                                 |                     |        |
| Yes                      | 5491 (21.2)                                               | 3343 (35.5)                                                   | 62.2                                            | 1.22 (1.15–1.30)    | <0.01  |
| No                       | 13,252 (51.1)                                             | 6073 (64.5)                                                   | 68.6                                            |                     |        |
| Dyslipidemia             |                                                          |                                                               |                                                 |                     |        |
| Yes                      | 5296 (20.4)                                               | 3681 (38.1)                                                   | 59.0                                            | 1.40 (1.32–1.50)    | <0.01  |
| No                       | 13,447 (51.8)                                             | 5735 (60.9)                                                   | 70.1                                            |                     |        |
| Charlson comorbidity index|                                                        |                                                               |                                                 |                     |        |
| ≤ 2                      | 13,253 (51.1)                                             | 6157 (65.4)                                                   | 68.3                                            |                     |        |
| 3                        | 3009 (11.6)                                               | 1514 (16.1)                                                   | 66.5                                            | 0.88 (0.82–1.00)    | <0.01  |
| ≥ 4                      | 2481 (9.6)                                                | 1745 (18.5)                                                   | 58.7                                            | 0.69 (0.64–0.70)    | <0.01  |
| Hospital information     |                                                          |                                                               |                                                 |                     |        |
| Patient volume per year  |                                                          |                                                               |                                                 |                     |        |
| < 50                     | 2149 (8.3)                                                | 844 (9.0)                                                     | 71.8                                            |                     |        |
| 50–100                   | 4634 (17.9)                                               | 2065 (21.9)                                                   | 69.2                                            | 0.95 (0.87–1.10)    | 0.36   |
| 100–150                  | 3587 (14.6)                                               | 2039 (21.7)                                                   | 65.0                                            | 0.89 (0.81–1.00)    | 0.03   |
| 150–200                  | 2863 (11.0)                                               | 1249 (13.3)                                                   | 69.6                                            | 1.13 (1.01–1.30)    | 0.03   |
| ≥ 200                    | 5310 (20.5)                                               | 3219 (34.2)                                                   | 62.3                                            | 0.87 (0.79–1.00)    | <0.01  |
| Region                   |                                                          |                                                               |                                                 |                     |        |
| Hokkaido                 | 1007 (3.9)                                                | 497 (5.3)                                                     | 67.0                                            |                     |        |
| Tohoku                   | 911 (3.5)                                                 | 326 (3.5)                                                     | 73.6                                            | 1.25 (1.05–1.50)    | 0.01   |
| Kantō                    | 5561 (21.4)                                               | 3971 (42.2)                                                   | 58.3                                            | 0.76 (0.67–0.90)    | <0.01  |
| Chubu                    | 3252 (12.5)                                               | 1207 (12.8)                                                   | 72.9                                            | 1.31 (1.15–1.50)    | <0.01  |
| Kinki                    | 3821 (14.7)                                               | 1662 (17.7)                                                   | 69.7                                            | 1.18 (1.04–1.30)    | 0.01   |
| Chugoku                  | 1378 (5.3)                                                | 547 (5.8)                                                     | 71.6                                            | 1.30 (1.12–1.50)    | <0.01  |
| Shikoku                  | 380 (1.5)                                                 | 93 (1.0)                                                      | 80.3                                            | 1.69 (1.31–2.20)    | <0.01  |
| Kyushu                   | 2433 (9.4)                                                | 1113 (11.8)                                                   | 68.6                                            | 0.96 (0.84–1.10)    | 0.59   |
length is much shorter than the six-month follow-up period set as an inclusion criterion for studies that provide high-quality evidence of the efficacy of CR.

While most CR programs around the world include pharmacological and nutritional education as core components, their implementation in real-world settings has not been clarified. Our study found that over 90% of CR participants were provided with pharmacological education, whereas only two-thirds were provided with nutritional education. Although the proportion of nutritional education provided to elderly individuals and women was lower than men, this result was reversed after adjusting for other covariates in the multivariable analysis. This is probably due to the fact that women are more likely to be elderly than men, and the proportion of critically ill patients with more comorbidities is higher among elderly individuals; i.e., they are more likely to be admitted to larger hospitals (which are more likely to accept such patients). Moreover, the patient to dietitian ratio is generally higher in larger hospitals, which could mean that it is more difficult to provide individualized services, such as nutritional guidance. This finding might be related to the scarcity of nutrition professionals working in a CR team. Further studies to clarify the association between care aspects and health care professionals are warranted.

The strengths of this study include the large sample size, generalizability of the results to the Japanese population, and detailed information on clinical practice due to the use of NDB data. However, there are also several limitations worth noting. First, we did not exclude patients who died in hospitals, as these patients could not be accurately identified in the database. This may have resulted in an overestimation of the number of patients who were considered eligible for CR. Second, there may have been other factors associated with CR participation which were not examined in this study, such as income status of patients and smoking history. Third, detailed hospital- and community-level information could not be obtained due to limitations of the database. For example, factors such as auto-referral systems may affect CR participation. Finally, since the present study used claims data, services not reimbursed by national health insurance, such as home-based CR and pharmacological and nutritional education by health care professionals other than pharmacists and dietitians, were not included in the present analysis, which might have led to underestimation of CR implementation and participation.

Conclusion
In Japan, participation in CR after PCI or CABG is limited, with only one-third of eligible patients participating in CR and for an insufficient duration. Patients who underwent CABG were more likely to participate in CR than those who underwent PCI. Our findings suggest that there is room for improvement in the provision of nutritional education as part of CR, and that there is a need to promote CR implementation in the future.

Data availability
The dataset analyzed in this study is not publicly available and can only be accessed by people approved by the Ministry of Health, Labour and Welfare in a limited environment, but is available from the corresponding author upon reasonable request.

Received: 24 May 2021; Accepted: 22 September 2021
Published online: 11 October 2021

References
1. The top 10 causes of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
2. Ministry of Health, Labour and Welfare: Handbook of Health and Welfare Statistics. https://www.mhlw.go.jp/english/database/db- hh/1-2.html.
3. Inohara, T. et al. Comparative trends in percutaneous coronary intervention in Japan and the United States, 2013 to 2017. J. Am. Coll. Cardiol. 76, 1328–1340 (2020).
4. Ogata, S. et al. Explaining the decline in coronary heart disease mortality rates in Japan: contributions of changes in risk factors and evidence-based treatments between 1980 and 2012. Int. J. Cardiol. 291, 183–188 (2019).
5. Yasuda, S., Miyamoto, Y. & Ogawa, H. Current status of cardiovascular medicine in the Aging Society of Japan. Circulation 138, 965–967 (2018).
6. Komuro, I. et al. Nationwide actions against heart failure pandemic in Japan—what should we do from Academia?. Circ. J. 83, 1819–1821 (2019).
7. Kimura, K. et al. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Circ. J. 83, 1085–1196 (2019).
8. Anderson, L. et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD001800.pub3 (2016).
9. Anderson, L. et al. Patient education in the management of coronary heart disease. Cochrane Database Syst. Rev. 6, CD008895 (2017).
10. Candelaria, D., Randall, S., Ladak, L. & Gallagher, R. Health-related quality of life and exercise-based cardiac rehabilitation in contemporary acute coronary syndrome patients: a systematic review and meta-analysis. Qual. Life Res. 29, 579–592 (2020).
11. Thomas, R. J. et al. 2018 ACC/AHA clinical performance and quality measures for cardiac rehabilitation: a report of the American College of Cardiology/American heart association task force on performance measures. Circ. Cardiovasc. Qual. Outcomes 11, e00037 (2018).
12. Piepoli, M. F. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 37, 2315–2381 (2016).
13. Overview | Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease | Guidance | NICE. https://www.nice.org.uk/guidance/cg172.
14. Woodruffe, S. et al. Australian Cardiovascular Health and Rehabilitation Association (ACRA) core components of cardiovascular disease secondary prevention and cardiac rehabilitation 2014. Heart Lung Circ. 24, 430–441 (2015).
15. Mehra, V. M., Gaslema, D. E., Pakosh, M. & Grace, S. L. Systematic review of cardiac rehabilitation guidelines: quality and scope. Eur. J. Prev. Cardiol. https://doi.org/10.1177/2047483319878958 (2019).
16. Suaya, J. A. et al. Use of cardiac rehabilitation by medicare beneficiaries after myocardial infarction or coronary bypass surgery. Circulation 116, 1653–1662 (2007).
17. Turk-Adawi, K., Sarrafzadegan, N. & Grace, S. L. Global availability of cardiac rehabilitation. Nat. Rev. Cardiol. 11, 586–596 (2014).
18. Aragam, K. G. et al. Gaps in referral to cardiac rehabilitation of patients undergoing percutaneous coronary intervention in the United States. J. Am. Coll. Cardiol. 65, 2079–2088 (2015).
19. Grace, S. L. et al. Cardiac rehabilitation delivery model for low-resource settings. Heart 102, 1449–1455 (2016).
20. Beatty, A. L., Bradley, S. M., Maynard, C. & McCabe, J. M. Referral to cardiac rehabilitation after percutaneous coronary intervention, coronary artery bypass surgery, and valve surgery: data from the clinical outcomes assessment program. Circ. Cardiovasc. Qual. Outcomes 10, 113 (2017).
21. Abreu, A. et al. Cardiac rehabilitation availability and delivery in Europe: How does it differ by region and compare with other high-income countries?: Endorsed by the European Association of Preventive Cardiology. Eur J Prev Cardiol 26, 1131–1146 (2019).
22. de Santiago, A. P. C., Chaves, G. S., Davies, P., Taylor, R. S. & Grace, S. L. Interventions to promote patient utilisation of cardiac rehabilitation. Cochrane Database Syst. Rev. 2019, 1096 (2019).
23. Santiago de APC., et al. Promoting patient utilization of outpatient cardiac rehabilitation: a joint International Council and Canadian Association of Cardiovascular Prevention and Rehabilitation position statement. Int. J. Cardiol. 298, 1–7 (2020).
24. Goto, Y. et al. Poor implementation of cardiac rehabilitation despite broad dissemination of coronary interventions for acute myocardial infarction in Japan: a nationwide survey. Circ. J. 71, 173–179 (2007).
25. Kanazawa, N., Ueshima, K., Tominari, S. & Nakayama, T. Underuse of cardiac rehabilitation in workers with coronary artery disease-claims database survey in Japan. Circ. J. 81, 1424–1431 (2017).
26. Endo, N., Goto, A., Suzuki, T., Matsuda, S. & Yasumura, S. Factors associated with enrollment and adherence in outpatient cardiac rehabilitation in Japan. J. Cardiopulm Rehabil. Prev. 35, 186–192 (2015).
27. Suzuki, S. et al. Evaluation of tooth loss among patients with diabetes mellitus using the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Int. Dent. J. 70, 308–315 (2020).
28. Kajimoto, T. & Kitajima, T. Patient and National economic burden of Dengue in Japan: results from Japanese National claims database. Am. J. Trop. Med. Hyg. 102, 1237–1243 (2020).
29. Hayashi, Y. et al. How was cognitive behavioural therapy for mood disorder implemented in Japan? A retrospective observational study using the nationwide claims database from FY2010 to FY2015. BMJ Open 10, e033365 (2020).
30. Suwani, H., Watanabe, R., Sato, M., Odawara, M. & Matsumura, H. DPP-4 inhibitor reduces the risk of developing hypertrophic scars and keloids following median sternotomy in diabetic patients: a nationwide retrospective cohort study using the national database of health insurance claims of Japan. Plast. Reconstr. Surg. https://doi.org/10.1097/PRS.0000000000006904 (2020).
31. Nishioka, Y. et al. Absolute risk of acute coronary syndrome after severe hypoglycemia: a population-based 2-year cohort study using the National Database in Japan. J. Diabetes Investig. 11, 426–434 (2020).
32. Kubo, S. et al. National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB): Outline and Patient-Matching Technique. https://doi.org/10.1101/280008 (2018).
33. Ohtera, S., Kanazawa, N., Otaza, N., Ueshima, K. & Nakayama, T. Proposal of quality indicators for cardiac rehabilitation after acute coronary syndrome in Japan: a modified Delphi method and practice test. BMJ Open 7, e013036 (2017).
34. Sundararajan, V. et al. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J. Clin. Epidemiol. 57, 1288–1294 (2004).
35. Grace, S. L. et al. Feasibility of assessing 2 cardiac rehabilitation quality indicators. J. Cardiopulm Rehabil. Prev. 36, 112–116 (2016).
36. Zecchin, R. et al. Development of quality indicators for cardiac rehabilitation in Australia: a modified delphi method and pilot test. Heart Lung Circ. 28, 1622–1630 (2019).
37. Ruano-Ravina, A. et al. Participation and adherence to cardiac rehabilitation programs. A systematic review. Int. J. Cardiol. 223, 436–443 (2016).
38. Goto, Y. Current state of cardiac rehabilitation in Japan. Prog. Cardiovasc. Dis. 56, 557–562 (2014).
39. Dunlay, S. M., Pack, Q. R., Thomas, R. J., Killian, J. M. & Roger, V. L. Participation in cardiac rehabilitation, readmissions, and death after acute myocardial infarction. Am. J. Med. 127, 538–546 (2014).
40. Ritchey, M. D. et al. Tracking cardiac rehabilitation participation and completion among medicare beneficiaries to inform the efforts of a National initiative. Circ. Cardiovasc. Qual. Outcomes 13, e005902 (2020).
41. Kanoaka, K. et al. Current status and effect of outpatient cardiac rehabilitation after percutaneous coronary intervention in Japan. Circ. Rep. 3, 122–130 (2021).
42. Ministry of Health, Labour and Welfare. Analysis of regional differences in health care costs (2018).
43. Tamaki, J. et al. Estimates of hip fracture incidence in Japan using the National Health Insurance Claim Database in 2012–2015. Osteoporos Int. 30, 975–983 (2019).
44. Anderson, L. et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst. Rev. 6, CD007130 (2017).
45. Pesah, E., Supervia, M., Turk-Adawi, K. & Grace, S. L. A review of cardiac rehabilitation delivery around the world. Prog. Cardiovasc. Dis. 60, 267–280 (2017).
46. Clark, A. M. et al. Factors influencing referral to cardiac rehabilitation and secondary prevention programs: a systematic review. Eur. J. Prev. Cardiol. 20, 692–700 (2013).
47. Liu, H. et al. Automated referral to cardiac rehabilitation after coronary artery bypass grafting is associated with modest improvement in program completion. Can. J. Cardiol. 35, 1491–1498 (2019).

Acknowledgements
We thank the Ministry of Health, Labour and Welfare for providing the data. This work was supported by Japan Society for the Promotion of Science (JPS) KAKENHI Grant Numbers JP18K17317 and JP20H03911. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author contributions
Conception, design, analysis, interpretation of the data, and writing the article: S.O.; critical revision of the article: G.K., H.U., Y.M., Y.N., N.O., T.N, and T.K.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-99516-1.

Correspondence and requests for materials should be addressed to G.K.

Reprints and permissions information is available at www.nature.com/reprints.
Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021